A critical review of 69 articles confirmed CBD's efficacy for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in children, with most side effects mild to moderate and transient.
Parents of children with refractory epilepsy, pediatric neurologists
RCT-confirmed efficacy for 3 epilepsy syndromes
What the researchers found
CBD efficacy for treating seizures has been confirmed by RCTs for LGS, Dravet syndrome, and TSC. Side effects are frequent but mostly mild to moderate and transient. There is no global consensus on regulatory approval, but CBD is considered promising with a good safety profile.
Why it matters
For families of children with treatment-resistant epilepsy, knowing that CBD has been confirmed effective through rigorous clinical trials provides evidence-based guidance in a landscape full of unproven claims.
The numbers in context
69 articles reviewed; efficacy confirmed for LGS, Dravet, TSC; side effects mostly mild-moderate and transient
How the study worked
Critical literature review of 69 articles from PubMed, Cochrane, and SciELO databases, without date, language, or study design restrictions, covering CBD for refractory epilepsy in pediatric populations.
What this study cannot tell us
Review focused on published literature which may have publication bias. Long-term safety data in pediatric populations remain limited.
How to read the evidence
Comprehensive review of 69 articles including randomized controlled trials that led to regulatory approvals.
When this study was published
Published in 2022
The bigger picture
While CBD has become the most successful cannabinoid medicine to date, regulatory approaches vary globally. The evidence base continues to support expanding access for children with these specific epilepsy syndromes.
Questions still open
- Could CBD be effective for other childhood epilepsy syndromes beyond the three approved indications? What are the long-term neurodevelopmental effects of chronic CBD use in children?
Common questions
Does CBD work for children with epilepsy?
Is CBD safe for children?
Read the original research
Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.
Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 41, e2021197
Citation
Moreira, Gabriela Araujo; Moraes Neto, Roddie; Ribeiro, Ricardo Gullit; Crippa, Ana Chrystina De Souza. (2022). Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 41, e2021197. https://doi.org/10.1590/1984-0462/2023/41/2021197
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk